Intellia Therapeutics Delivers a Q4 Beat

Core Insights - Intellia Therapeutics reported better-than-expected fourth-quarter results, driven by increased collaboration revenue [1][7] Financial Performance - The company reported a net loss of $1.27 per share, which was better than the analysts' expectation of a$1.34 loss, and revenue of $12.9 million, significantly exceeding the$7 million estimate [1][2] - R&D expenses rose to $116.9 million, a 7.3$109 million in Q4 2023 [2][8] - For the full year, collaboration revenue reached $57.9 million, up from$36.3 million in 2023 [7] Company Overview and Strategy - Intellia utilizes CRISPR/Cas9 technology to develop gene-editing treatments for genetic diseases, focusing on lead programs NTLA-2001 and NTLA-2002 [3] - The company has prioritized late-stage programs and plans to reduce its workforce by about 27% in 2025 to align resources with core priorities [4] Clinical Developments - In Q4, Intellia initiated dosing in its global Phase 3 HAELO study for NTLA-2002, aiming for a 2027 U.S. market launch [5] - The MAGNITUDE Phase 3 trial for NTLA-2001 showed promising results with a 90% mean serum TTR reduction [6] Outlook - As of December 31, Intellia had a cash position of $861.7 million, projected to sustain operations through the first half of 2027 [9]